| P50 | author | Hans Erik Johnsen | Q43196325 |
| | Michael Toft Overgaard | Q47805032 |
| | Ken Maes | Q56489332 |
| | Eline Menu | Q56697627 |
| | Elke De Bruyne | Q58658192 |
| P2093 | author name string | Els Van Valckenborgh | |
| | Karin Vanderkerken | |
| | Liesbeth Bieghs | |
| | Olle Larsson | |
| | Mette Nyegaard | |
| | Magnus Axelson | |
| | Rik Schots | |
| | Helena Jernberg-Wiklund | |
| | Karel Fostier | |
| | Susanne Lub | |
| P2860 | cites work | The Bcl-2 apoptotic switch in cancer development and therapy | Q24620437 |
| | ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets | Q27683708 |
| | An inhibitor of Bcl-2 family proteins induces regression of solid tumours | Q29547595 |
| | ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor | Q29616727 |
| | Drug combination studies and their synergy quantification using the Chou-Talalay method | Q29617422 |
| | Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity | Q33392920 |
| | Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease | Q33398808 |
| | ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia | Q33405436 |
| | Reprogramming cell death: BCL2 family inhibition in hematological malignancies | Q33410744 |
| | Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation | Q33952805 |
| | Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA. | Q35107469 |
| | Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells | Q35153790 |
| | Multiple myeloma biology: lessons from the 5TMM models | Q35170944 |
| | Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transpla | Q35848978 |
| | Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. | Q36333522 |
| | Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse | Q36430970 |
| | BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma | Q36658048 |
| | BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells | Q36677926 |
| | Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1. | Q36711639 |
| | The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor | Q37215171 |
| | Bcl-2 family proteins and cancer | Q37310180 |
| | Involvement of BH3-only proteins in hematologic malignancies | Q37330909 |
| | The role of the insulin-like growth factor 1 receptor axis in multiple myeloma | Q37398728 |
| | Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. | Q37451892 |
| | Latest advances and current challenges in the treatment of multiple myeloma | Q37986287 |
| | The HDAC inhibitor LBH589 enhances the antimyeloma effects of the IGF-1RTK inhibitor picropodophyllin. | Q39384823 |
| | Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: in vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737. | Q39433633 |
| | ABT-737 is highly effective against molecular subgroups of multiple myeloma | Q39491434 |
| | ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents | Q39494067 |
| | The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo | Q39748438 |
| | IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms. | Q39750237 |
| | The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. | Q40178770 |
| | Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival | Q40206938 |
| | The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells | Q40508757 |
| | Myeloid cell factor-1 is a critical survival factor for multiple myeloma | Q40655990 |
| | The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma | Q42748426 |
| | Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma | Q42762683 |
| | Tumor-initiating capacity of CD138- and CD138+ tumor cells in the 5T33 multiple myeloma model | Q43008917 |
| | Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation | Q44926251 |
| | Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model | Q45280801 |
| | IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. | Q46706373 |
| | Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. | Q52546411 |
| | A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. | Q53595735 |
| | Lentivirally transduced dendritic cells as a tool for cancer immunotherapy | Q60858599 |
| P433 | issue | 22 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 11193-11208 | |
| P577 | publication date | 2014-11-01 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic | |
| P478 | volume | 5 | |